FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Lilly diabetes med linked to pancreatitis

Tools

A fast-growing Eli Lilly med may be held back by a new warning linking it to acute pancreatitis. After 30 reports of pancreatitis in patients using the injectable diabetes drug Byetta--five of which led to serious complications such as kidney failure--the FDA has asked Lilly and its partner on the drug, Amylin, to revise its labeling.

With $430.2 million in 2006 sales, Byetta delivered some $219 million in revenues to Lilly. The rest went to Amylin, accounting for 90 percent of that company's sales. Amylin stock fell sharply on the news.

- check out the report from the Indianapolis Star

Related Articles:
In speech, Lilly CEO calls for drug monitoring. Report
Lilly developing biotech drugs the old-fashioned way. Report
Amylin shares shoot up on Phase II Byetta results. Report
Diabetes epidemic triggers soaring drug market. Report

Read more on: Eli Lilly | Diabetes | Amylin

More stories about Eli Lilly   FDA warning   Byetta   Amylin   Diabetes   FDA   FDA regulation  

Comments

i was wondering if you could help us, the pharmcist referred me to you my son is diebetic and takes insulin daily but he does not have any insurance is there any discount program we coud go on please feel free to contact me at 708-227-4324 THANK YOU VERY MUCH

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 50 + 26?
To combat spam, please solve the math question above.